Hermetica Superfood Encyclopedia
The Short Answer
Piliostigma reticulatum leaf extracts contain high-concentration phenolic compounds (74.66 ± 1.76 µg GAE/mL) alongside flavonoids, tannins, alkaloids, and terpenoids that drive free radical scavenging, protein denaturation inhibition, and direct antimicrobial activity. In vitro studies demonstrate exceptional antioxidant potency with a DPPH IC₅₀ of 8.88 ± 0.11 µg/mL—substantially outperforming standard reference compounds—and MIC values of 15.625–250 µg/mL against a range of bacterial pathogens.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordPiliostigma reticulatum benefits
Piliostigma reticulatum — botanical close-up
Health Benefits
**Antioxidant Activity**
Methanolic leaf extracts exhibit potent free radical scavenging capacity with DPPH IC₅₀ of 8.88 ± 0.11 µg/mL and ABTS IC₅₀ of 9.78 ± 1.83 µg/mL, outperforming ascorbic acid standards (IC₅₀ 30.76 ± 0.18 µg/mL); this activity is primarily attributed to the high phenolic and flavonoid content.
**Antibacterial Effects**: Methanolic and dichloromethane fractions of P
reticulatum demonstrate broad-spectrum antibacterial activity with MIC values ranging from 15.625 to 250 µg/mL, with the dichloromethane fraction producing inhibition zones of 13.3 ± 0.67 mm against E. coli and 13.2 ± 0.76 mm against V. cholerae at 60 mg/mL; tannins and phenolics are believed to disrupt bacterial membrane integrity.
**Anti-inflammatory Properties**
In vitro albumin denaturation inhibition assays reveal an IC₅₀ of 121.43 ± 1.55 µg/mL, broadly comparable to diclofenac sodium as a reference anti-inflammatory agent; flavonoids and polyphenols are the likely mediators of this protein-stabilizing effect.
**Favorable Safety Profile**
Acute oral toxicity studies in animal models established an LD₅₀ exceeding 5000 mg/kg body weight, classifying extracts as practically non-toxic under the Globally Harmonized System; hematological and biochemical markers showed no significant alterations at tested doses.
**Polyphenol-Rich Nutritional Composition**
Total polyphenol contents across plant organs span 47–578 mg GAE/g and total flavonoid contents range 30–435 mg QE/g depending on organ and extraction method, indicating exceptional phytochemical density relevant to antioxidative and cytoprotective applications.
**Potential Antimicrobial Against Cholera-Associated Pathogens**: Specific efficacy against V. cholerae (13.2 ± 0.76 mm inhibition zone) aligns with traditional West African use in regions where waterborne infections are endemic, supporting ethnopharmacological rationale for its inclusion in the West African pharmacopeia.
**Pharmaceutical-Grade Plant Drug Quality**
Powdered plant material meets acceptable quality standards with 7–10% total ash content and titratable acidity of 2.3–3.6 mg/g, supporting its use as a standardizable botanical raw material for formulation development.
Origin & History
Natural habitat
Piliostigma reticulatum is a deciduous shrub or small tree native to the semi-arid and sub-Sahelian regions of West Africa, including Senegal, Mali, Burkina Faso, Nigeria, and Ghana, where it thrives in savanna woodlands and degraded lands with poor soils. It is highly drought-tolerant and often associated with agroforestry systems, where it contributes to soil nitrogen fixation as a leguminous species in the family Fabaceae (subfamily Caesalpinioideae). The plant grows commonly on sandy to lateritic soils and is used across rural communities as both a fodder tree and a source of traditional medicine.
“Piliostigma reticulatum holds an established position in the West African pharmacopeia, particularly among communities in Senegal, Mali, Burkina Faso, and neighboring Sahelian nations, where it is known regionally as 'Mampa' in some linguistic contexts and used alongside its sister species P. thonningii for overlapping medicinal indications. Traditional healers have employed preparations of the leaves, bark, and roots for the management of infectious diseases, wound healing, gastrointestinal ailments, and inflammatory conditions, often in the form of decoctions or macerations administered orally or topically. The plant's wide availability as a drought-resistant agroforestry species has made it an accessible and economically important medicinal resource for rural and peri-urban populations with limited access to pharmaceutical healthcare. Its shared pharmacopoeial status across multiple West African ethnic groups and linguistic communities underscores cultural consensus regarding its therapeutic utility, though systematic ethnobotanical documentation remains incomplete in international scientific literature.”Traditional Medicine
Scientific Research
The current evidence base for P. reticulatum consists entirely of in vitro laboratory studies and preclinical animal toxicity evaluations, with no published human clinical trials or randomized controlled trials identified as of the most recent literature review. In vitro studies have quantified antioxidant capacity (DPPH and ABTS assays), antibacterial MICs against clinically relevant strains including E. coli, V. cholerae, and others, and anti-inflammatory activity via albumin denaturation inhibition, providing reproducible and internally consistent preliminary data. Acute and sub-chronic toxicity studies in rodent models support a favorable safety profile (LD₅₀ > 5000 mg/kg), but extrapolation to human dosing remains speculative without pharmacokinetic, bioavailability, or dose-escalation studies in humans. The overall evidence quality is preclinical, placing P. reticulatum at an early stage of scientific validation; ethnobotanical documentation in the West African pharmacopeia context provides supportive contextual evidence but does not substitute for controlled clinical investigation.
Preparation & Dosage
Traditional preparation
**Methanolic Leaf Extract (Research Grade)**
Used at 100 µg/mL in in vitro assays to achieve 85.89% DPPH inhibition; no standardized human dose has been established from clinical trials.
**Dichloromethane Fraction**
60 mg/mL in antibacterial disk diffusion research; not a form suitable for oral supplementation and cited here only for scientific context
Applied at .
**Traditional Aqueous Decoction**
Historically prepared by boiling dried leaves or bark in water, a preparation common across West African ethnomedicine for infectious and inflammatory complaints; exact volumes and concentrations are undocumented in peer-reviewed literature.
**Powdered Plant Drug**
Extract yields of 7–18% from plant material have been reported in research settings, indicating moderate phytochemical extractability; no commercial standardized extract with defined polyphenol percentages is currently available.
**Dosage Guidance**
5000 mg/kg in animals suggests a wide theoretical safety margin, but this does not establish an effective or recommended human dose
No clinically validated dosage range exists for human use; the acute oral LD₅₀ > .
**Timing**
No data available on optimal administration timing relative to meals or circadian factors.
Nutritional Profile
Piliostigma reticulatum leaves are phytochemically rich rather than nutritionally dense in the classical macronutrient sense; total polyphenol content ranges from 47 to 578 mg GAE/g dry weight across plant organs, and total flavonoid content spans 30 to 435 mg QE/g, values that rank among the higher end reported for African medicinal plants. Specific phenolic content in methanolic leaf extracts measures 74.66 ± 1.76 µg GAE/mL, exceeding that of sister species P. thonningii (56.54 ± 1.24 µg GAE/mL). Fatty acids including palmitic acid (C16:0) and stearic acid (C18:0) have been identified by spectroscopic analysis alongside abeitic acid (a diterpene resin acid), sesquiterpenes, tannins, alkaloids, saponins, terpenoids, and glycosides. Bioavailability of phenolic constituents from traditional aqueous decoctions has not been studied; polyphenol absorption is expected to be influenced by gut microbiota-mediated biotransformation, food matrix interactions, and the specific glycosylation state of flavonoids present.
How It Works
Mechanism of Action
The antioxidant activity of P. reticulatum is mediated primarily by phenolic hydroxyl groups that donate hydrogen atoms to neutralize reactive oxygen species (ROS) in both DPPH and ABTS radical systems, with the exceptionally low IC₅₀ values (~8–9 µg/mL) suggesting multiple redox-active compounds acting synergistically. Antibacterial effects are attributed to membrane-disrupting activity of tannins and terpenoids, which bind to and precipitate bacterial surface proteins, alter membrane permeability, and chelate essential metal ions required for bacterial enzyme function, as evidenced by concentration-dependent MIC data. Anti-inflammatory activity proceeds through inhibition of heat-induced albumin denaturation, a proxy for stabilization of lysosomal membranes and prevention of inflammatory mediator release, with flavonoids and polyphenols likely acting as inhibitors of cyclooxygenase and lipoxygenase pathways at the cellular level. Sesquiterpenes, palmitic acid, stearic acid, and abeitic acid identified via spectroscopic analysis may contribute additional membrane-modulatory and immunomodulatory effects, though their specific molecular targets have not yet been characterized in peer-reviewed mechanistic studies.
Clinical Evidence
No human clinical trials have been conducted on P. reticulatum to date; all available efficacy data derive from cell-free assay systems and animal toxicity models. The in vitro findings—particularly DPPH IC₅₀ of 8.88 µg/mL, ABTS IC₅₀ of 9.78 µg/mL, and antibacterial MICs down to 15.625 µg/mL—are internally consistent and methodologically sound but cannot be directly translated to clinical dose-response relationships without human pharmacokinetic data. Sub-chronic animal studies showed no hematological or biochemical abnormalities, providing an acceptable preclinical safety signal, but effect sizes in human populations, optimal therapeutic doses, and long-term safety remain entirely unknown. Confidence in clinical efficacy is therefore low; the ingredient warrants prospective ethnopharmacological documentation and Phase I/II human studies before evidence-based therapeutic recommendations can be made.
Safety & Interactions
Acute oral toxicity studies in animal models established an LD₅₀ greater than 5000 mg/kg body weight, the highest category of practical non-toxicity under GHS classification, and sub-chronic exposure produced no detectable alterations in hematological or biochemical markers at tested doses. No human adverse event data, drug interaction studies, or controlled safety trials exist; therefore, contraindications, drug–herb interaction profiles, and long-term safety in human populations cannot be characterized from available evidence. The high tannin content in extracts raises a theoretical concern for reduced absorption of co-administered iron, zinc, and certain pharmaceutical drugs (including antibiotics and anticoagulants) if taken concurrently, based on known tannin pharmacology, but this has not been directly studied for P. reticulatum. Pregnant and lactating individuals should avoid use in the absence of any safety data for these populations; individuals on anticoagulant, antibiotic, or anti-inflammatory drug regimens should exercise caution given potential polyphenol–drug interactions, and a maximum safe human dose has not been established.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Piliostigma reticulatum (DC.) Hochst.Bauhinia reticulata DC.MampaCamel's foot tree (West African variant)
Frequently Asked Questions
What is Piliostigma reticulatum used for medicinally?
Piliostigma reticulatum is used in West African traditional medicine for infectious diseases, wound healing, gastrointestinal conditions, and inflammatory complaints, typically as leaf or bark decoctions. Modern in vitro research supports antibacterial activity (MICs 15.625–250 µg/mL), potent antioxidant effects (DPPH IC₅₀ 8.88 µg/mL), and anti-inflammatory activity (albumin denaturation IC₅₀ 121.43 µg/mL), although no human clinical trials have confirmed these effects.
Is Piliostigma reticulatum safe to consume?
Animal toxicity studies show an acute oral LD₅₀ greater than 5000 mg/kg body weight, classifying it as practically non-toxic, and sub-chronic exposure produced no changes in hematological or biochemical markers. However, no human safety data, drug interaction studies, or maximum safe dose recommendations exist, and individuals who are pregnant, lactating, or taking prescription medications should consult a healthcare provider before use.
How does Piliostigma reticulatum compare to its sister species P. thonningii?
Piliostigma reticulatum consistently shows higher phytochemical concentrations than P. thonningii; for example, phenolic content in methanolic leaf extracts measures 74.66 ± 1.76 µg GAE/mL for P. reticulatum versus 56.54 ± 1.24 µg GAE/mL for P. thonningii. Both species share overlapping traditional medicinal applications in West African pharmacopeia and are sometimes used interchangeably or in combination by traditional healers.
What are the main bioactive compounds in Piliostigma reticulatum?
The primary bioactive constituents are phenolics (highest concentration at 74.66 ± 1.76 µg GAE/mL in methanolic leaf extract), followed by alkaloids, tannins, terpenoids, flavonoids, and saponins, with total polyphenols reaching up to 578 mg GAE/g and flavonoids up to 435 mg QE/g across plant organs. Spectroscopic analysis has also identified sesquiterpenes, palmitic acid, stearic acid, and abeitic acid as secondary constituents.
Are there any clinical trials on Piliostigma reticulatum?
No human clinical trials have been published on Piliostigma reticulatum as of the current literature review; all available scientific evidence is limited to in vitro assays and preclinical animal toxicity studies. While these preliminary findings are promising, the absence of pharmacokinetic data, bioavailability studies, and randomized controlled trials means that evidence-based therapeutic dosing and confirmed clinical efficacy cannot yet be established.
How does the antioxidant potency of Piliostigma reticulatum compare to common antioxidant supplements?
Piliostigma reticulatum leaf extracts demonstrate superior antioxidant activity compared to ascorbic acid, with DPPH IC₅₀ values of 8.88 ± 0.11 µg/mL versus ascorbic acid's 30.76 ± 0.18 µg/mL, making it approximately 3.5 times more potent. This exceptional free radical scavenging capacity is driven by its high phenolic and flavonoid content. The ABTS assay similarly shows strong performance with IC₅₀ of 9.78 ± 1.83 µg/mL, indicating robust antioxidant potential across multiple oxidative stress models.
What form of Piliostigma reticulatum extract provides the most active antimicrobial benefits?
Methanolic and dichloromethane fractions of Piliostigma reticulatum have demonstrated the strongest antibacterial effects in research studies. These solvent-based extracts appear to concentrate the bioactive compounds responsible for antimicrobial activity more effectively than other preparation methods. The specific solvent extraction process directly influences which antimicrobial compounds are isolated and their relative concentration in the final extract.
Which populations may benefit most from Piliostigma reticulatum supplementation based on its bioactive profile?
Individuals seeking potent antioxidant support and those concerned with bacterial-related health challenges may benefit most from Piliostigma reticulatum due to its superior free radical scavenging capacity and documented antibacterial properties. The herb's high phenolic and flavonoid content makes it particularly valuable for people looking to address oxidative stress-related conditions. However, individuals on antibacterial medications or those with specific health conditions should consult healthcare providers before use.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w piliostigma-reticulatum-piliostigma-reticulatum curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
